Key Developments: Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

442.30INR
3:51am EDT
Price Change (% chg)

Rs3.00 (+0.68%)
Prev Close
Rs439.30
Open
Rs440.00
Day's High
Rs445.95
Day's Low
Rs439.30
Volume
64,796
Avg. Vol
222,741
52-wk High
Rs460.45
52-wk Low
Rs366.70

Search Stocks

Latest Key Developments (Source: Significant Developments)

Cipla Ltd Wins Patent Opposition Against Pfizer Inc.'s Cancer Drug-Business Standard
Thursday, 4 Oct 2012 07:37am EDT 

Business Standard reported that the Indian patent office has revoked US-based Pfizer Inc's patent for cancer drug Sutent in India. The patent office has rejected Pfizer's claim for the patent over Sutent, saying Pfizer's patent does not involve any inventive step. The post-grant opposition was filed by Mumbai-based Cipla Ltd and Natco Pharma. Against the decision, Pfizer India will appeal before Intellectual Property Appellate Board (IPAB).  Full Article

Cipla Ltd Wins Cancer Drug Patent Case Against Roche Holding AG-The Economic Times
Saturday, 8 Sep 2012 09:11am EDT 

The Economic Times reported that Cipla Ltd says it has scored a court win in a patent challenge launched by Switzerland's Roche Holding AG over the Mumbai firm's version of a lung-cancer drug. Delhi High Court Justice Manmohan Singh on Friday ruled that Cipla's drug, Erlocip, did not violate the Roche patent on its anti-lung cancer medication Tarceva due to its different molecular make-up. No further details of the judgment were available.  Full Article

UPDATE 1-S.African govt awards $33 mln respiratory contract to Cipla

CAPE TOWN, June 26 - South Africa has awarded Cipla Medpro a 345 million rand ($32.6 million) share in the national respiratory tender as Africa's most advanced economy seeks to cut high asthma mortality rates, the company said on Thursday.

Search Stocks